Jay Luly, Enanta CEO

Enan­ta culls in­ter­nal NASH work, bet­ting on an out-li­cens­ing strat­e­gy in the dis­as­ter-strewn field

Crack­ing NASH has been the holy grail for years in liv­er drug de­vel­op­ment, but the field has so far proven a waste­land for biotech. One biotech is now of­fload­ing in-house clin­i­cal work for two of its NASH drugs af­ter one post­ed lack­lus­ter re­sults as a so­lo ther­a­py.

Enan­ta Phar­ma­ceu­ti­cals has halt­ed in­ter­nal de­vel­op­ment of its two FXR ag­o­nist NASH drugs, EDP-305 and fol­low-up can­di­date EDP-297, and will piv­ot to an out-li­cens­ing strat­e­gy af­ter ear­ly da­ta turned up lit­tle chance of suc­cess for ei­ther drug as a so­lo agent, the com­pa­ny said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.